title: Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
abstract: BACKGROUND
  Cinacalcet is an effective treatment for hypercalcemia due to persistent hyperparathyroidism (HPT) in patients who have undergone kidney transplantation (KT). Few data are available about their long-term follow-up.
  
  
  OBJECTIVE
  We aimed to evaluate the long-term efficacy of cinacalcet in functioning stable KT subjects with hypercalcemia secondary to persistent HPT.
  
  
  METHODS
  Twenty-three patients (6 men) with a stable KT showed persistent hypercalcemia (>12 months) secondary to HPT (parathyroid hormone by radioimmunoassay [iPTH] > 150 pg/mL). The mean age was 54 ± 13 years. Time after KT to beginning cinacalcet treatment was 36.5 ± 37.9 (range 12 to 172) months. Initial cinacalcet doses were 30 mg/d. Median follow-up was 53 ± 7.4 months (range 42 to 60 months). We determined serum calcium, phosphorus, alkaline phosphatase, iPTH, creatinine, and immunosuppressant concentrations at baseline as well as 3, 6, and 12 months and after every 6 months thereafter.
  
  
  RESULTS
  Initial serum calcium was 11 ± 0.65 mg/dL and mean calcium during treatment, 10.25 ± 0.81 mg/dL (P < .001). Initial serum phosphorus was 2.8 ± 0.58 mg/dL and mean value serum phosphorus during the treatment period, 3.13 ± 0.6 mg/dL (P = 0.015). Initial iPTH was 260 ± 132 pg/mL and during the treatment period; 237 ± 131 pg/mL (P = ns). There was no change in renal function nor in immunosuppressant blood levels. Doses of cinacalcet at the end of the follow-up were 40.4 ± 18.9 mg/d.
  
  
  CONCLUSIONS
  Cinacalcet was effective for long-term control of hypercalcemia related to persistent HPT for patients with stable KT.
authors.affiliation: Nephrology and Kidney Transplantation Unit, Hospital Clinic, Barcelona, Spain.
authors.forename: R P
authors.initials: RP
authors.lastname: Paschoalin
authors.forename: J-V
authors.initials: JV
authors.lastname: Torregrosa
authors.forename: A
authors.initials: A
authors.lastname: Sánchez-Escuredo
authors.forename: X
authors.initials: X
authors.lastname: Barros
authors.forename: C E
authors.initials: CE
authors.lastname: Durán
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D057966:Calcimimetic Agents / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000209:etiology*; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011863:Radioimmunoassay; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D057966:Calcimimetic Agents; D007166:Immunosuppressive Agents; D009281:Naphthalenes; C470125:PTH protein, human; D010281:Parathyroid Hormone; D010758:Phosphorus; D003404:Creatinine; D000469:Alkaline Phosphatase; D002118:Calcium; D000069449:Cinacalcet